ArticleScientific reports2026
Dysregulated Fas/Fas ligand expression in endometrial stromal cells and mononuclear cells in endometriosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apoptosis plays a paramount role in endometriosis pathogenesis. This process may be disrupted in endometrial stromal cells (ESCs) of women with endometriosis, causing them to continue developing in ectopic locations. This study investigates the role of apoptosis in endometriosis by comparing the protein expression of Fas (CD95) and Fas ligand (FasL) in ESCs of women with endometriosis to that of healthy controls. Additionally, it examines the gene expression levels of Fas and FasL in peritoneal fluid mononuclear cells (PFMCs) and peripheral blood mononuclear cells (PBMCs) from both groups. Lastly, it assesses the levels of soluble FasL (sFasL) released by ESCs and PFMCs. ESCs were isolated from ectopic (n = 11) and eutopic samples (n = 17) of endometriosis patients and control (n = 10), alongside peritoneal fluid and blood samples from 10 patients and 10 controls. Using Western blot, Fas and FasL protein expression were assessed in ectopic endometrial stromal cells (EESCs), eutopic endometrial stromal cells (EuESCs), and control endometrial stromal cells (CESCs). Additionally, quantitative real-time PCR was used to evaluate Fas and FasL gene expression in PFMCs and PBMCs. Lastly, an enzyme-linked immunosorbent assay (ELISA) was conducted to assess the concentration of sFasL molecules in the supernatants of EESCs, EuESCs, CESCs, and PFMCs. Importantly, Fas protein levels in EESCs and EuESCs were lower than in CESCs (p < 0.01). Conversely, FasL protein levels were elevated in EESCs compared to both EuESCs and CESCs (p < 0.01 and p < 0.05, respectively). Additionally, patients with endometriosis exhibited higher Fas gene expression in PFMCs (p < 0.05) and lower expression in PBMCs (p < 0.01) compared to controls, along with reduced FasL expression in PFMCs (p < 0.01). Moreover, the concentration of sFasL molecules released from EESCs was significantly higher compared to EuESCs (p < 0.01) and CESCs (p < 0.05). All in all, our findings shed light on the understanding of the involvement of the Fas/FasL pathway in endometriosis pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.